
Software velocity is not simply a development challenge. It is becoming an enterprise capability.
Software is increasingly driving differentiation, recurring revenue, and customer value in MedTech. But many organizations are still trying to develop and release software through operating models designed for long-cycle hardware.
The result is a growing mismatch: agile software teams operating inside rigid funding models, sequential quality processes, and late-stage regulatory gates.
This Executive Brief examines what it takes to close that gap—drawing on McKinsey’s analysis of the future of Software as a Medical Device (SaMD).
Key highlights covered in the audio brief:
* The hardware operating model does not translate cleanly to SaMD. Long development cycles, fixed requirements, and late-stage validation can undermine the speed and iterative advantage that make software valuable.
* “Shift left” changes the role of Quality and Regulatory. Design controls, risk management, documentation, and compliance activities move into the development workflow rather than being performed primarily at the end.
* Agile quality can create measurable capacity. The report cites substantial reductions in testing, administrative effort, and change-control cycle time—potentially releasing additional developer capacity without simply adding headcount.
* Agentic AI could become part of the quality infrastructure. Specialized agents may assist with translating requirements, drafting documentation, identifying potential risks, and maintaining traceability across rapidly changing software systems.
* AI remains an augmentation strategy—not an autonomous compliance function. Human quality, regulatory, clinical, and engineering experts must continue to review, validate, and make the consequential decisions.
* Funding models may need to change as much as development models. Software portfolios benefit from continuous business-case review and resource allocation based on market feedback and development velocity rather than rigid multi-year investment plans.
* The hardest transformation may be cultural. Embedding Quality inside agile product teams requires changes in incentives, accountability, leadership behavior, and the traditional relationship between engineering and compliance functions.
Executive takeaway
Scaling Software as a Medical Device requires more than faster development. It demands an operating model that integrates quality and risk management into agile workflows, uses AI to reduce compliance burdens, and supports continuous investment decisions.
The competitive advantage will belong to organizations that can deliver regulated software faster without compromising safety or compliance.
Keywords
Software as a Medical Device (SaMD), MedTech, Agile Quality, Shift Left, Agentic AI, Design Controls, Risk Management, Regulatory Strategy, Software Lifecycle, Digital Transformation
🎧Listen to the Executive Brief for a closer look at how shift-left quality, agile operating models, and emerging agentic AI capabilities could reshape the economics and execution of Software as a Medical Device.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.
Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* McKinsey & Company (2026). The future of delivering software as a medical device. McKinsey’s Life Sciences Practice.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
More episodes from "Let's Talk Risk! Podcast"



Don't miss an episode of “Let's Talk Risk! Podcast” and subscribe to it in the GetPodcast app.








